A double-headed cathepsin B inhibitor devoid of warhead.
Most synthetic inhibitors of peptidases have been targeted to the active site for inhibiting catalysis through reversible competition with the substrate or by covalent modification of catalytic groups. Cathepsin B is unique among the cysteine peptidase for the presence of a flexible segment, known as the occluding loop, which can block the primed subsites of the substrate binding cleft. With the occluding loop in the open conformation cathepsin B acts as an endopeptidase, and it acts as an exopeptidase when the loop is closed. We have targeted the occluding loop of human cathepsin B at its surface, outside the catalytic center, using a high-throughput docking procedure. The aim was to identify inhibitors that would interact with the occluding loop thereby modulating enzyme activity without the help of chemical warheads against catalytic residues. From a large library of compounds, the in silico approach identified [2-[2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino]-2-oxoethyl] 2-(furan-2-carbonylamino) acetate, which fulfills the working hypothesis. This molecule possesses two distinct binding moieties and behaves as a reversible, double-headed competitive inhibitor of cathepsin B by excluding synthetic and protein substrates from the active center. The kinetic mechanism of inhibition suggests that the occluding loop is stabilized in its closed conformation, mainly by hydrogen bonds with the inhibitor, thus decreasing endoproteolytic activity of the enzyme. Furthermore, the dioxothiazolidine head of the compound sterically hinders binding of the C-terminal residue of substrates resulting in inhibition of the exopeptidase activity of cathepsin B in a physiopathologically relevant pH range.
Schenker
Patricia
P
Department of Biochemistry, University of Zurich, CH-8057 Zurich, Switzerland.
Alfarano
Pietro
P
Kolb
Peter
P
Caflisch
Amedeo
A
Baici
Antonio
A
D000595:Amino Acid Sequence; D001667:Binding, Competitive; D002401:Cathepsin B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D003198:Computer Simulation; D007700:Kinetics; D008969:Molecular Sequence Data; D019151:Peptide Library; D011480:Protease Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D011487:Protein Conformation; D054730:Protein Interaction Domains and Motifs; D053778:Thiazolidines / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*
C534988:(2-(2-(2,4-dioxo-1,3-thiazolidin-3-yl)ethylamino)-2-oxoethyl) 2-(furan-2-carbonylamino)acetate; D019151:Peptide Library; D011480:Protease Inhibitors; D053778:Thiazolidines; D002401:Cathepsin B
EMBO J. 1991 Sep;10(9):2321-30
1868826
Biochem J. 1980 Jul 1;189(1):17-25
7458901
Biochem J. 1983 Aug 1;213(2):467-71
6351842
Biol Chem Hoppe Seyler. 1988 May;369 Suppl:257-61
3264507
J Biol Chem. 1986 Jul 15;261(20):9375-81
3522589
Anal Biochem. 1973 Jun;53(2):484-90
4716383
J Biol Chem. 2000 Mar 17;275(11):8154-60
10713138
J Med Chem. 2005 Aug 11;48(16):5108-11
16078830
Biol Chem. 2003 Jul;384(7):1007-18
12956417
J Comput Chem. 2004 Feb;25(3):412-22
14696075
Biochemistry. 1999 Apr 20;38(16):5017-23
10213604
Biochem J. 1978 Jun 1;171(3):759-65
666735
Biol Chem. 2006 Aug;387(8):1017-21
16895470
Biol Chem. 1998 Aug-Sep;379(8-9):1007-18
9792432
Clin Cancer Res. 2005 May 1;11(9):3155-62
15867207
Anal Biochem. 2005 May 1;340(1):1-13
15802124
J Biol Chem. 1997 Jan 10;272(2):1197-202
8995421
J Am Chem Soc. 2006 Apr 26;128(16):5436-43
16620115
Eur J Biochem. 1995 Apr 15;229(2):533-9
7744077
Biochem J. 2002 Feb 1;361(Pt 3):613-9
11802791
Drug Discov Today. 2006 Jul;11(13-14):607-15
16793529
FEBS Lett. 2000 Dec 29;487(2):156-60
11150500
Biochemistry. 1997 Oct 14;36(41):12608-15
9376367
FEBS Lett. 1997 Dec 15;419(2-3):231-4
9428640
Proteins. 1999 Oct 1;37(1):88-105
10451553
Biochem J. 1980 Jun 1;187(3):909-12
6897924
Nat Rev Cancer. 2006 Oct;6(10):764-75
16990854
J Biol Chem. 2004 Sep 24;279(39):41012-7
15262981
FEBS Lett. 1993 Jun 21;324(3):325-30
8405375
Biochem J. 1996 Aug 1;317 ( Pt 3):901-5
8760380
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82
15667143
Blood. 1984 Jan;63(1):88-95
6418236
Bioorg Chem. 2002 Aug;30(4):264-75
12392705
J Med Chem. 2008 Mar 13;51(5):1179-88
18271520
Biol Chem. 2001 Sep;382(9):1365-72
11688719
Curr Med Chem. 2006;13(19):2309-27
16918357
Ann Rheum Dis. 1995 Apr;54(4):289-97
7763107
Cancer Res. 2006 Jul 1;66(13):6699-707
16818644
Biol Chem. 2003 Jun;384(6):845-54
12887051
Biochem J. 1998 Nov 1;335 ( Pt 3):491-4
9794785
Biochim Biophys Acta. 1965 Jul 29;105(1):193-5
4221326
FEBS Lett. 1991 Mar 25;280(2):307-10
2013328
FEBS Lett. 1996 Apr 22;384(3):211-4
8617355
J Clin Invest. 2003 Jun;111(11):1733-45
12782676
FEBS Lett. 1998 Jan 23;422(1):61-4
9475170
Biopolymers. 1999;51(1):99-107
10380357
Anal Biochem. 2007 Dec 1;371(1):43-51
17706587
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D160-4
14681384
Anal Biochem. 2004 Dec 15;335(2):244-52
15556563
Eur J Biochem. 1981 Sep;119(1):9-14
7341250
Biochem J. 1993 Sep 15;294 ( Pt 3):923-7
8379946
Histochem Cell Biol. 2003 Feb;119(2):93-101
12610728
Ann Rheum Dis. 1995 Apr;54(4):281-8
7763106
J Med Chem. 2006 Dec 14;49(25):7384-92
17149868
J Biol Chem. 2002 Jun 14;277(24):21389-96
11932257
Biochem Biophys Res Commun. 1967 Apr 20;27(2):157-62
6035483
Chem Rev. 1997 Feb 5;97(1):133-172
11848867